Blog

New Horizons in Psychedelic Research: VETS' Groundbreaking Collaborations in 2025

In 2024, the landscape of psychedelic-assisted therapy expanded in ways that few could have imagined. As we approach 2025, VETS is proud to lead the charge in groundbreaking research and transformative outcomes. As the New Year approaches, we’d like to highlight several exciting research projects on the horizon.

A Thousand Stories of Hope and Healing: VETS' Journey from Vision to Transformation

The transformation of VETS from one family's healing journey to a leading force in veteran care symbolizes more than just organizational growth—it represents hundreds of lives transformed, families restored, and hope renewed. As we look toward serving our 1,000th grant recipient, we remain committed to our ultimate goal: ensuring that every veteran has access to the healing they deserve.

Coaching and Therapy in Psychedelic-Assisted Healing: Distinct, Complementary Roles for Holistic Support

Coaching and therapy are distinct, yet complementary, approaches to enhancing individual well-being and personal growth. Therapy and coaching are both valuable forms of support—but they serve different purposes, utilize different treatment modalities, focus on different aspects of personal development, and have vastly different educational requirements. Let’s talk about these differences.

Paradigm Shift: Psilocybin-Assisted Therapy’s New Potential for Treating Complex Symptomology

Psychedelic-assisted therapies have shown great potential to remediate symptomology across a spectrum of mental health conditions. Researchers are beginning to exemplify the “transdiagnostic antidepressant, anxiolytic, and anti-addictive therapeutic potential” of psychedelics by developing crosscutting protocols for addressing a multitude of conditions.

Navigating Complexity: Reflections on the FDA's MDMA-Assisted Therapy Decision and the Future of Psychedelic Medicine

The FDA’s recent decision to decline approval for MDMA-assisted therapy for PTSD, while disappointing, is not the end of the road. The agency’s request for further research serves as a reminder of the hurdles we still face in advancing psychedelic medicine through regulatory channels.